Liu Guohui, Rosenberger William F, Haines Linda M
Department of Biostatistics, Millennium Pharmaceuticals, Inc. 40 Landsdowne Street, Cambridge, MA 02139, USA.
Biom J. 2009 Apr;51(2):335-47. doi: 10.1002/bimj.200800192.
Sequential designs for phase I clinical trials which incorporate maximum likelihood estimates (MLE) as data accrue are inherently problematic because of limited data for estimation early on. We address this problem for small phase I clinical trials with ordinal responses. In particular, we explore the problem of the nonexistence of the MLE of the logistic parameters under a proportional odds model with one predictor. We incorporate the probability of an undetermined MLE as a restriction, as well as ethical considerations, into a proposed sequential optimal approach, which consists of a start-up design, a follow-on design and a sequential dose-finding design. Comparisons with nonparametric sequential designs are also performed based on simulation studies with parameters drawn from a real data set.
随着数据积累纳入最大似然估计(MLE)的I期临床试验序贯设计,由于早期用于估计的数据有限,本质上存在问题。我们针对具有有序反应的小型I期临床试验解决这个问题。特别地,我们探讨了在具有一个预测变量的比例优势模型下逻辑参数的MLE不存在的问题。我们将未确定MLE的概率作为一种限制,以及伦理考量,纳入一种提议的序贯优化方法中,该方法由一个启动设计、一个后续设计和一个序贯剂量寻找设计组成。还基于从真实数据集抽取参数的模拟研究,与非参数序贯设计进行了比较。